Cardiac Stunning After Electrical Cardioversion

The Association Between Myocardial Stunning and Long-term Prognosis After Electrical Cardioversion in Patients with Atrial Fibrillation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06752733

Acronym

AMPEA

Enrollment

160

Registered

2024-12-31

Start date

2024-02-20

Completion date

2026-08-31

Last updated

2024-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (AF)

Brief summary

The goal of this observational study is to evaluate cardiac stunning and electrocardiographic parameters through transthoracic echocardiography and 24 hours ECG conducted immediately following electrical cardioversion. The main question it aims to answer is: Do echocardiographic and electrocardiographic parameters relating to cardiac stunning predict atrial fibrillation (AF) recurrence rates after electrical cardioversion? Participants will undergo echocardiography and a 24-hour Holter monitoring immediately after electrical cardioversion.

Interventions

PROCEDUREelectrical cardioversion

synchronized electrical shocks to restore normal sinus rhythm in patients with atrial fibrillation, performed under sedation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with atrial fibrillation * Patients with persistent or symptomatic atrial fibrillation who are candidates for electrical cardioversion * Patients eligible for anticoagulation therapy for thromboembolism prevention before and after the procedure * Patients who can understand and provide written informed consent

Exclusion criteria

* Patients under 18 years of age or over 80 years of age * Patients who do not consent to participate in the study * Patients with severe coronary artery stenosis * Patients with severe hepatic dysfunction * Patients with severe renal dysfunction * Patients with severe valvular heart disease * Patients with a high risk of severe bleeding * Patients with a history of atrial fibrillation-related catheter ablation or cardiac surgery * Patients with an expected life expectancy of less than 1 year * Potentially pregnant individuals * Patients deemed unsuitable for the study by the investigator

Design outcomes

Primary

Measure	Time frame
The recurrence of atrial arrhythmia	From enrollment to the end of treatment at 12 months

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026